Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
- JPWA Shows Firm Opposition to Annual Revisions
December 5, 2016
- Annual Price Revisions of All Drugs Unacceptable: JMA Chief
December 1, 2016
- Japan, US, Europe Trade Groups Vehemently Oppose Annual Price Revisions
December 1, 2016
- JGA Rebuts Govt Panel Members’ Pricing Reform Proposals in Emergency Statement
November 30, 2016
- Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
November 28, 2016
- EFPIA, PhRMA “Regret” Out-of-Cycle Price Slash for Opdivo
November 22, 2016
- EFPIA Japan Lauds MHLW Task Force’s Proposal on Blood Products and Vaccines Industries
November 22, 2016
- JPMA to Straighten Up Industry Positions on FY2018 Pricing Reform
November 18, 2016
- Opdivo Price Cut “Unavoidable” to Maintain Universal Healthcare: JMA Chief
November 18, 2016
- FPMAJ, JPMA Issue Joint Statement on Emergency Price Cut for Opdivo
November 17, 2016
- Drug Costs Is Main Culprit of Ballooning Medical Spending: Hodanren
November 16, 2016
- Japan Society of Generic Medicines Calls for Lawmaker-Sponsored Bill to Push Biosimilar Use
November 14, 2016
- PhRMA, EFPIA Members Conducted 825 Japan Clinical Trials in 2015
November 8, 2016
- Japan Biosimilar Association Draws Gradual Rise in Membership, Mixed Interests
November 7, 2016
- Realtor-Led Tokyo Life Sciences Hub Initiative Aims to Fill Void between Academia, Pharmas
October 27, 2016
- Japan Should Adopt French-Type HTA: JMA Exec Suzuki
October 26, 2016
- No Plan to Respond to MHLW Task Force’s Proposal on Vaccine, Blood Product Industries: JPMA
October 21, 2016
- Keidanren Wades into Pricy Med Debate, Calls for Quick Price Review
October 17, 2016
- Govt and Industry Should Generate Ideas Together: EFPIA Japan Chief
October 7, 2016
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…